Daiichi Sankyo Company, Limited · TSE:4568

Daiichi Sankyo — 2018 Deutsche Bank Virtual Investor Conference

57 slides from Daiichi Sankyo's conference presentation, Nov 15, 2018

  1. Slide 1: Vision, Business Plan and Progress

    Vision, Business Plan and Progress DAIICHI SANKYO CO., LTD. Junichi Onuma Senior Director, IR Group November, 15 2018

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements Management strategies and plans, financial forecasts, future projections and policies, and R&D information that Daiichi Sankyo discloses in this material are all classified as Daiichi Sankyo’s future prospects. These forward looking statements were determined by Daiichi Sa

  3. Slide 3: Agenda

    Agenda  About Daiichi Sankyo  2025 Vision and 5-Year Business Plan (5YBP)  Revised Target for 5YBP 3

  4. Slide 4: About Daiichi Sankyo

     About Daiichi Sankyo 4

  5. Slide 5: About Daiichi Sankyo

    About Daiichi Sankyo A Japanese Pharmaceutical Company  Headquarters: Nihonbashi, Tokyo, Japan  Chairman & CEO: Mr. George Nakayama  President & COO: Dr. Sunao Manabe  Revenue: US $8.73 Bn (JPY 960.2 Bn)  Operating profit: US $694 Mn (JPY 76.3 Bn)*  Listed on Tokyo Stock Exchange (Ticker code

  6. Slide 6: Our History – Road after the Merger

    Our History – Road after the Merger Sankyo pravastatin Daiichi Sankyo 1899~ (Mevalotin/Pravachol) 2005~ antihyperlipidemic agent Olmesartan (Olmetec/Benicar) antihypertensive agent 1989 levofloxacin Daiichi (Cravit/Levaquin) Edoxaban synthetic antibacterial agent (Lixiana/Savaysa) 1915~ anticoagulan

  7. Slide 7: Employees and Bases

    Employees and Bases As of Mar. 2018 14,446 Worldwide Employees Europe Japan North 1,582 8,765 America 2,191 - Germany - UK - Ireland - France Asia - Spain 1,553 - Portugal - Italy South & Central - Netherlands - China America - Belgium - South Korea - Austria - Taiwan 355 - Switzerland - Hong Kong -

  8. Slide 8: FY2017 Financial Results

    FY2017 Financial Results (Bn JPY) Revenue 960.2 100.0% Others 9.1% Cost of Sales 346.0 36.0% Europe SG&A Expenses 301.8 31.4% 8.3% R&D Expenses 236.0 24.6% North Revenue America Operating Profit 76.3 7.9% JPY 960.2 Bn Japan Profit before Tax 81.0 8.4% 18.8% 63.8% Profit attributable to owners of the

  9. Slide 9: 2025 Vision and 5-Year Business Plan (5YBP)

     2025 Vision and 5-Year Business Plan (5YBP) 9

  10. Slide 10: 2025 Vision: Global Pharma Innovator with Competitive Advantage in Oncology

    2025 Vision Global Pharma Innovator with Competitive Advantage in Oncology  Build a specialty area* centered on oncology as the core business  Enrich regional value aligned with market needs  Create innovative products – change SOC (Standard of Care)  Realize shareholder value through highly eff

  11. Slide 11: 5-Year Business Plan (FY2016 - FY2020)

    5-Year Business Plan (FY2016 - FY2020) Challenge 1: Grow beyond the LOE of olmesartan Challenge 2: Establish a foundation of sustainable growth Revenue 1,100.0 Bn JPY Revenue 986.4 Bn JPY Revenue Increase value of late- 910.0 stage pipeline* Bn JPY OP *3 - 5 products launched within the next 5 years

  12. Slide 12: Strategic Targets

    Strategic Targets ~For establishing foundation of sustainable growth~  Grow Edoxaban  Grow as No.1 company in Japan  Expand US Businesses  Establish Oncology Business  Continuously Generate Innovative Medicine Changing SOC (Standard of Care)  Enhance Profit Generation Capabilities 12

  13. Slide 13: Strategic Targets

    Strategic Targets ~For establishing foundation of sustainable growth~  Grow Edoxaban  Grow as No.1 company in Japan  Expand US Businesses  Establish Oncology Business  Continuously Generate Innovative Medicine Changing SOC (Standard of Care)  Enhance Profit Generation Capabilities 13

  14. Slide 14: Edoxaban: Growth in Japan

    Edoxaban: Growth in Japan Sales  As of FY2018 Q2, Edoxaban (brand name in JP: Lixiana) closed in on No.1 sales share (%) 50 40 31.3% 30 30.7% 20 Lixiana Product A 10 Product B Product C 0 Copyright © 2018 IQVIA. Calculated based on JPM FY2014 Q1 - FY2018 Q2 Reprinted with permission 14

  15. Slide 15: Edoxaban: Growth in Each Country/Region

    Edoxaban: Growth in Each Country/Region Volume Edoxaban volume (DoT) % share of DOAC markets over time 30% 25.1% S. Korea 25% 23.9% Japan 20% 14.3% Taiwan 13.3% Belgium 15% 13.1% Germany 10% 10.5% Italy 10.1% Spain 5% 3.9% UK 0.3% USA 0% Brazil: Launched in Aug. 2018 Copyright © 2018 IQVIA. Calculat

  16. Slide 16: Edoxaban: FY2020 Target

    Edoxaban: FY2020 Target Expanding mainly in Japan, EU and Asia 120.0 Bn JPY 111.0 (1 Bn USD) Bn JPY anticoagulant agent Edoxaban (Lixiana/Savaysa) 77.1 Bn JPY 37.3 Bn JPY 15.0 Bn JPY FY2015 FY2016 FY2017 FY2018 FY2020 Results Results Results Forecast 5-Year Business Plan Target Conservative assumpti

  17. Slide 17: Strategic Targets

    Strategic Targets ~For establishing foundation of sustainable growth~  Grow Edoxaban  Grow as No.1 company in Japan  Expand US Businesses  Establish Oncology Business  Continuously Generate Innovative Medicine Changing SOC (Standard of Care)  Enhance Profit Generation Capabilities 17

  18. Slide 18: Japan Business: 6 Major Products

    Japan Business: 6 Major Products Share Share Share No.1 No.1 No.1* Nexium Memary Pralia ulcer treatment Alzheimer’s disease treatment treatment for osteoporosis Share No.1 Ranmark Efient Tenelia treatment for bone complication antiplatelet agent type 2 diabetes mellitus inhibitor caused by bone meta

  19. Slide 19: Headwind of Drug Pricing System in JP

    Headwind of Drug Pricing System in JP  Introduced Special expansion re-pricing  Limited application of Price Maintenance Premium (PMP)  Further price pressure on long-listed drugs  Price revision may occur every year 19

  20. Slide 20: Japan Business: Major Products FY2020 Target

    Japan Business: 6 Major Products FY2020 Target  Major factors changed from original assumption 243.0  Nexium: Special expansion re-pricing Bn JPY 212.8 212.0 Bn JPY Bn JPY 197.3 Bn JPY 171.1 Bn JPY FY2015 FY2016 FY2017 FY2018 FY2020 Results Results Results Forecast 5-Year Business Plan Target 20

  21. Slide 21: Strategic Targets

    Strategic Targets ~For establishing foundation of sustainable growth~  Grow Edoxaban  Grow as No.1 company in Japan  Expand US Businesses  Establish Oncology Business  Continuously Generate Innovative Medicine Changing SOC (Standard of Care)  Enhance Profit Generation Capabilities 21

  22. Slide 22: Two Business Units in US

    Two Business Units in US Daiichi Sankyo, Inc. (DSI) (Basking Ridge, NJ) FY2018 revenue forecast: US$ 281 Mn With the LOE of key products, Daiichi Sankyo, Inc. will transition from a mature primary care company to one with a differentiated specialty portfolio centered on Pain and Oncology Luitpold Ph

  23. Slide 23: Injectafer: Sales Team

    Injectafer: Sales Team In Jan. 2017, LPI sales team for Injectafer became DSI employees: Now DSI and LPI are a united sales team for Injectafer Women’s Chronic IBD/ Heart ND-CKD Oncology Health GI Failure Cardiologist Gastro Nephrologist OBGYN Oncologist Infusion Center Patient referral IDA treatmen

  24. Slide 24: Luitpold Business: FY2020 Target

    Luitpold Business: FY2020 Target Realize rapid and sustainable growth with Iron franchise and Generic injectable franchise 1,250 Mn USD (150.0 Bn JPY) 1,026 Mn USD (113.0 Bn JPY) 951 Mn USD (105.4 Bn JPY) 812 Mn USD (88.1 Bn JPY) 758 Mn USD (91.0 Bn JPY) Luitpold will change the company name to “Ame

  25. Slide 25: Pain Franchise: FY2020 Target

    Pain Franchise: FY2020 Target  CL-108 > 100 Bn JPY in FY2020  Decided to return all of rights regarding CL-108  Mirogabalin  Did not meet the primary efficacy endpoint 4.2 2.0 Bn JPY Bn JPY FY2015 FY2016 FY2020 Results Results Target 25

  26. Slide 26: Strategic Targets

    Strategic Targets ~For establishing foundation of sustainable growth~  Grow Edoxaban  Grow as No.1 company in Japan  Expand US Businesses  Establish Oncology Business  Continuously Generate Innovative Medicine Changing SOC (Standard of Care)  Enhance Profit Generation Capabilities 26

  27. Slide 27: Oncology Business: FY2020 Target

    Oncology Business: FY2020 Target By FY2025 Increase revenue to 300.0 bn JPY or more By FY2020 Increase revenue to 40.0 Bn JPY or more FY2015 FY2017 FY2020 FY2025 27

  28. Slide 28: Current Progress of 5-Year Business Plan: Oncology Business

    Current Progress of 5-Year Business Plan: Oncology Business  Built 3 pillars of oncology business, ADC Franchise, AML Franchise and Breakthrough Science, and focus investments on the pillars ADC AML Breakthrough Franchise Franchise Science • Highly promising pipeline • Rich pipeline • Rich pipeline

  29. Slide 29: ADC technology: Mode of Action (MOA)

    ADC technology: Mode of Action (MOA)  ADC technology has broad application across multiple types of cancer  Designed to deliver enhanced cancer cell destruction with less systemic exposure to chemotherapy Antigen Target cancer cell Endosome Bind to antigen Internalization Endolysosome Antibody Dru

  30. Slide 30: DS's Proprietary ADC technology

    DS’s Proprietary ADC technology Proprietary Drug-Linker O O OH O N O O O O N H H H CysS N N N N N N O N H H H O O O O F Cysteine residue Drug-Linker O H O NH O N Conjugation chemistry F N O The linker is connected to cysteine residue of the O H O antibody Proprietary payload (DXd) Exatecan derivativ

  31. Slide 31: ADC Franchise

    ADC Franchise ADC Franchise Clinical stage Project Pre- Potential Indication Discovery Phase 1 Pivotal (Target) Clinical DS-8201 Breast, Gastric, 1 (HER2) CRC, NSCLC U3-1402 2 Breast, NSCLC (HER3) DS-1062 3 (TROP2) NSCLC , DS-7300 4 Solid tumor (B7-H3) DS-6157 5 GIST (GPR20) DS-6000 Renal, 6 (undisc

  32. Slide 32: DS-8201: Clinical Program

    DS-8201: Clinical Program FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 Multiple Tumors P1 HER2 positive mBreast Post T-DM1 Pivotal P2 HER2 positive mBreast Post T-DM1 vs Phys Choice P3 Breast Global HER2 positive mBreast vs T-DM1 P3 HER2 low mBreast P3 HER2 expressing mGastric 3rd line vs Gastric Physi

  33. Slide 33: DS-8201: P1 Study Efficacy

    DS-8201: P1 Study Efficacy ASCO 2018 Presentation Tumor Shrinkage by Tumor Types: (5.4 or 6.4 mg/kg) 80 HER2-Positive Breast Cancer 80 HER2-Low Breast Cancer 60 C h a n g e fro m b a s e lin e ( % ) 60 C h a n g e fro m b a s e lin e ( % ) 40 N = 104 40 N = 33 20 20 0 0 -2 0 -2 0 -4 0 -4 0 -6 0 -6 0

  34. Slide 34: DS-8201: P1 Study Efficacy

    DS-8201: P1 Study Efficacy ASCO 2018 Presentation Efficacy Outcomes by Tumor Type (5.4 or 6.4 mg/kg) HER2-Expressing HER2-Positive BC HER2-Low BC HER2-Positive GC Other Cancers N = 111 N = 34 N = 44 N = 51 Confirmed ORR* % (n/N) 54.5% (54/99) 50.0% (17/34) 43.2% (19/44) 38.7% (12/31) DCR % (n/N) 93.

  35. Slide 35: DS-8201: Frequent TEAEs (≥20%)

    DS-8201: Frequent TEAEs (≥20%) (all tumor types from part 1 and part 2) All tumor types from P1 study part 1 and part 2; 5.4 or 6.4 mg/kga (N = 259) Any Grade, n (%) Grade ≥3, n (%) Nausea 192 (74.1) 9 (3.5) Decreased appetite 147 (56.8) 12 (4.6) Vomiting 113 (43.6) 6 (2.3) Anemia 98 (37.8) 50 (19.3

  36. Slide 36: DS-8201: Adverse Events of Special Interest

    DS-8201: Adverse Events of Special Interest (all tumor types from part 1 and part 2) All tumor types from P1 study part 1 and part 2; 5.4 or 6.4 mg/kga (N = 259) Any Grade, n (%) Grade ≥3, n (%) AST increased 53 (20.5) 4 (1.5) ALT increased 40 (15.4) 2 (0.8) Blood bilirubin increased 6 (2.3) 1 (0.4)

  37. Slide 37: DS-8201: Clinical Program

    DS-8201: Clinical Program FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 Multiple Tumors P1 HER2 positive mBreast Post T-DM1 Pivotal P2 HER2 positive mBreast Post T-DM1 vs Phys Choice P3 Breast Global HER2 positive mBreast vs T-DM1 P3 HER2 low mBreast P3 HER2 expressing mGastric 3rd line vs Gastric Physi

  38. Slide 38: DS-8201: HER2 Positive Metastatic Breast Cancer

    DS-8201:HER2 Positive Metastatic Breast Cancer HER2 positive metastatic Breast Cancer 1st line Herceptin (Trastuzumab) (+ Perjeta (Pertuzumab)) 2nd line HER2 positive mBreast Kadcyla (T-DM1) vs T-DM1 P3 Started HER2 positive mBareast Post T-DM1 Pivotal P2 3rd line Enrollment Completed Physician's Ch

  39. Slide 39: DS-8201: HER2 Low BC Phase 3 Target Population

    DS-8201:HER2 Low BC Phase 3 Target Population Patients with metastatic Breast Cancer Herceptin/Perjeta N=288,550 Kadcyla (T-DM1) HR- / HER2 positive HR+ / HER2 positive Scope of HER2 positive 6.8% 13.5% P2 pivotal and P3 studies N=19,730 N=38,835 HR- / HR+ / HER2 low Scope of HER2 Low HER2 low BC P3

  40. Slide 40: DS-8201: Clinical Program

    DS-8201: Clinical Program As of Oct 2018 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 Multiple Tumors P1 HER2 positive mBreast Post T-DM1 Pivotal P2 HER2 positive mBreast Post T-DM1 vs Phys Choice P3 Breast Global HER2 positive mBreast vs T-DM1 P3 HER2 low mBreast P3 HER2 expressing mGastric 3rd line v

  41. Slide 41: DS-8201: Other than Breast Cancer

    DS-8201: Other than Breast Cancer  Pivotal P2 study is on track Gastric  P3 study is under preparation  CRC: P2 study is on track CRC  NSCLC: P2 study is on track NSCLC  Started Opdivo (nivolumab) combo study IO  Signed Keytruda (pembrolizumab) combo Combo study alliance  Signed Bavencio (ave

  42. Slide 42: ADC Franchise

    ADC Franchise ADC Franchise Clinical stage Project Pre- Potential Indication Discovery Phase 1 Pivotal (Target) Clinical DS-8201 Breast, Gastric, 1 (HER2) CRC, NSCLC U3-1402 2 Breast, NSCLC (HER3) DS-1062 3 (TROP2) NSCLC , DS-7300 4 Solid tumor (B7-H3) DS-6157 5 GIST (GPR20) DS-6000 Renal, 6 (undisc

  43. Slide 43: U3-1402: BC P1/2 Study Efficacy

    U3-1402: BC P1/2 Study Efficacy ASCO 2018 Presentation Best Percentage Change in Sum of Diameters From Baseline in Target Lesions* Percentage Change in Sum of Longest Diameters Change in Target Lesions rom baseline (%) Maximum Change in Tumor Size 40 20 0 -20 (%) -40 -60 -80 ORR**: 15/32 (47%) -100

  44. Slide 44: U3-1402: BC P1/2 Study Safety

    U3-1402: BC P1/2 Study Safety ASCO 2018 Presentation Treatment-Emergent Blood and Liver related AE in ≥ 15% Patients, Dose Escalation Phase (Total N = 34)* All All Grade Grade Preferred Term Grades Preferred Term Grades ≥ 3 (%) ≥ 3 (%) (%) (%) Platelet count ALT increased 13 (38) 3 (9) 23 (68) 10 (2

  45. Slide 45: Summary of ADC Franchise 1/2

    Summary of ADC Franchise 1/2 DS-8201  Further evaluation in:  HER2+ mBC who failed Herceptin and/or Kadcyla  HER2 low mBC where there is no approved HER2 targeted therapy  Patient population is twice of HER 2 positive mBC  HER2 expressing mGC where Herceptin is only approved HER2 targeted thera

  46. Slide 46: Summary of ADC Franchise 2/2

    Summary of ADC Franchise 2/2  Showed similarity to earlier DS-8201 clinical data in P1 Breast study  P1 NSCLC study is on track U3-1402  2nd ADC to show clinical activity: proof of DS ADC technology as validated platform  DS-1062: P1 NSCLC study is on track Other ADC  DS-7300: Will start P1 stu

  47. Slide 47: Next Data Points and R&D Day

    Next Data Points and R&D Day December 1-3, 2018: American Society of Hematology (ASH) @ San Diego  AML Franchise: Multiple abstracts submitted (including Quizartinib QuANTUM-R) December 4-8, 2018: San Antonio Breast Cancer Symposium (SABCS)  DS-8201  P1 study BC HER2 positive/low update  Dose ju

  48. Slide 48: Revised Target for 5-Year Business Plan

    Revised Target for 5-Year Business Plan 48

  49. Slide 49: Current Progress of 5-Year Business Plan

    Current Progress of 5-Year Business Plan  Edoxaban: Growing in momentum beyond the initial target  Luitpold (US): Maintaining a high level growth  Oncology: Enriching our pipeline value including DS-8201  Pain Business (US): Difficult to achieve the initial target  Japan Business: Future busine

  50. Slide 50: Current Progress of 5-Year Business Plan: ADC Franchise

    Current Progress of 5-Year Business Plan: ADC Franchise  Established ADC technology as a platform technology  DS-8201: Accumulated promising clinical data  U3-1402: Disclosed promising preliminary clinical data  Increasing expectation on other ADCs ADC Franchise U3-1402 TA-MUC1 DS-7300 B7-H3 HER

  51. Slide 51: Oncology Business: Increase Investments

    Oncology Business: Increase Investments FY2018 - FY2022 (5 Years)  R&D Investments: 1.1 Tn JPY  Prioritize the investments to maximize the potential of ADC franchise  Capital Exp. to enhance oncology: 25.0 Bn JPY or more R&D Investments 1,100.0 Bn JPY 200.0 Bn JPY Additional investment to oncolog

  52. Slide 52: Oncology Business: Revenue Target

    Oncology Business: Revenue Target  Expand the future oncology revenue by accelerating and enhancing the investments Oncology <Original> Revenue Oncology Business: Revenue 500.0 FY2020: 40.0 Bn JPY Bn JPY FY2025: 300.0 Bn JPY Value of late-stage pipeline FY2020: 3-5 products with peak-sales of more

  53. Slide 53: 5-Year Business Plan (Original)

    5-Year Business Plan (Original)  Grow beyond FY2017 LOE of olmesartan 2025 Vision Global Pharma Innovator  Establish a foundation of sustainable growth with Competitive Advantage in Oncology Revenue 1,100.0 Bn JPY  Increase value of late-stage pipeline 3-5 products with peak-sales of Revenue more

  54. Slide 54: Revised Target for 5-Year Business Plan

    Revised Target for 5-Year Business Plan  Revised FY2020 Target 2025 Vision Global Pharma Innovator  Achieve original OP target two years behind with Competitive Advantage in Oncology Revenue 1,100.0  Increase value of late-stage Bn JPY pipeline Revenue Total expected revenue at peak 960.0 : 500.0

  55. Slide 55: Shareholder Returns

    Shareholder Returns Shareholder Returns Policy: FY2016 - FY2022 Annual ordinary Total return dividends Flexible Ratio* 70 JPY acquisition of own shares 100% or more or more  Annual ordinary dividends: 70 JPY dividend in FY2016 and FY2017  Acquisition of own shares: 50.0 Bn JPY in both FY2016 and F

  56. Slide 56: Toward 2025 Vision

    Toward 2025 Vision 2025 Vision 米国事業の拡大 Global Pharma Revenue 利益創出力の強化 Innovator with 1,100.0 Bn JPY Competitive Advantage Revenue in Oncology Revenue 960.0 910.0 Bn JPY Bn JPY OP 165.0 OP OP Bn JPY 78.0 80.0 Bn JPY Bn JPY FY2018 FY2020 FY2022 Forecast Target Target  Enhance investments and maximize

  57. Slide 57: Contact address regarding this material

    Contact address regarding this material Daiichi Sankyo Co., Ltd. Corporate Communications Department TEL: +81-3-6225-1126 Email: [email protected]

Daiichi Sankyo Company — 2018 Deutsche Bank Virtual Investor Conference on 6ix